NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
X4 Pharmaceuticals, Inc. XFOR
10 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$35.1M
▲ 1273.2% vs FY2024
EPS · FY25
$-1.87
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-76.0%
Net margin · FY25
-225.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 35.1M
Revenue, FY2025 · full 10-year series below
Revenue
Net income
The company lost 226 cents on every revenue dollar this year.
Per share
USD -1.87
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-76.0%
Return on equity, FY2025
ROE
Operating margin-247.4%
Net margin-225.6%
Return on assets-36.3%
Each USD of equity lost 76 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+63.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+63.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.09B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 290.5M
total assets, end of FY2025
Total assetsUSD 290.5M
EquityUSD 186.3M
CashUSD 217.0M
Gross debtUSD 75.0M
Net debtUSD -142.0M
Current ratio10.16×
The company holds more cash than debt.
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Operating income $B
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Net income $B
−0.1
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−1.87
−5.59
−17.07
−1.52
−3.99
−3.09
−4.63
−79.15
−54.58
−44.79
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
−76.0
−102.3
−161.7
−135.6
−129.3
−61.5
−202.6
·
·
·
Shares out B
0.09
0.01
0.17
0.12
0.03
0.02
0.00
0.00
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
28 of 28
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed